Curi RMB Capital LLC Sells 12,262 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Curi RMB Capital LLC significantly reduced its holdings in Edwards Lifesciences Corporation by 68.7%, selling 12,262 shares during the first quarter, leaving them with 5,576 shares valued at $404,000.
• Multiple institutional investors have increased their positions in Edwards Lifesciences, with ownership among institutional investors now at 79.46% of the company's stock.
• Edwards Lifesciences reported a quarterly earnings per share of $0.67, exceeding consensus estimates, with revenue of $1.53 billion, indicating an 11.9% year-over-year growth.

Curi RMB Capital LLC cut its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 68.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,576 shares of the medical research company's stock after selling 12,262 shares during the period. Curi RMB Capital LLC's holdings in Edwards Lifesciences were worth $404,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Allspring Global Investments Holdings LLC increased its holdings in Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after purchasing an additional 145 shares in the last quarter. Dynamic Advisor Solutions LLC raised its position in Edwards Lifesciences by 2.4% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock valued at $1,124,000 after buying an additional 370 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Edwards Lifesciences by 13.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock valued at $5,582,000 after acquiring an additional 9,188 shares in the last quarter. United Asset Strategies Inc. boosted its holdings in Edwards Lifesciences by 10.4% during the 1st quarter. United Asset Strategies Inc. now owns 185,571 shares of the medical research company's stock worth $13,450,000 after acquiring an additional 17,412 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its stake in shares of Edwards Lifesciences by 390.7% in the 1st quarter. Farther Finance Advisors LLC now owns 8,808 shares of the medical research company's stock worth $633,000 after acquiring an additional 7,013 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company's stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,014 shares of company stock worth $1,698,844 over the last quarter. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded down $0.51 during trading hours on Friday, reaching $77.50. The company had a trading volume of 6,301,589 shares, compared to its average volume of 3,595,766. The firm has a market cap of $45.50 billion, a PE ratio of 11.15, a price-to-earnings-growth ratio of 3.76 and a beta of 1.07. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The business has a fifty day simple moving average of $78.92 and a 200 day simple moving average of $75.39.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. During the same quarter in the prior year, the firm posted $0.70 EPS. The firm's quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Wells Fargo & Company lifted their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research report on Thursday, August 7th. The Goldman Sachs Group reiterated a "buy" rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Evercore ISI upped their price objective on Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a research note on Friday, July 25th. Canaccord Genuity Group raised their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a research report on Friday, July 25th. Finally, Robert W. Baird boosted their price target on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of "Moderate Buy" and a consensus target price of $86.26.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.